Cherubism as a systemic skeletal disease: evidence from an aggressive case.
Bone loss phenotype
Case report
Cherubism
SH3BP2 protein
Systemic inflammation
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
04
05
2020
accepted:
10
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Cherubism is a rare autosomal dominant genetic condition caused by mutations in the SH3BP2 gene. This disease is characterized by osteolysis of the jaws, with the bone replaced by soft tissue rich in fibroblasts and multinuclear giant cells. SH3BP2 is a ubiquitous adaptor protein yet the consequences of SH3BP2 mutation have so far been described as impacting only face. Cherubism mouse models have been generated and unlike human patients, the knock-in mice exhibit systemic bone loss together with a systemic inflammation. In light of these observations, we decided to search for a systemic cherubism phenotype in a 6-year-old girl with an aggressive cherubism. We report here the first case of cherubism with systemic manifestations. Bone densitometry showed low overall bone density (total body Z-score = - 4.6 SD). Several markers of bone remodelling (CTx, BALP, P1NP) as well as inflammation (TNFα and IL-1) were elevated. A causative second-site mutation in other genes known to influence bone density was ruled out by sequencing a panel of such genes. If this systemic skeletal cherubism phenotype should be confirmed, it would simplify the treatment of severe cherubism patients and allay reservations about applying a systemic treatment such as those recently published (tacrolimus or imatinib) to a disease heretofore believed to be localised to the jaws.
Sections du résumé
BACKGROUND
BACKGROUND
Cherubism is a rare autosomal dominant genetic condition caused by mutations in the SH3BP2 gene. This disease is characterized by osteolysis of the jaws, with the bone replaced by soft tissue rich in fibroblasts and multinuclear giant cells. SH3BP2 is a ubiquitous adaptor protein yet the consequences of SH3BP2 mutation have so far been described as impacting only face. Cherubism mouse models have been generated and unlike human patients, the knock-in mice exhibit systemic bone loss together with a systemic inflammation.
CASE PRESENTATION
METHODS
In light of these observations, we decided to search for a systemic cherubism phenotype in a 6-year-old girl with an aggressive cherubism. We report here the first case of cherubism with systemic manifestations. Bone densitometry showed low overall bone density (total body Z-score = - 4.6 SD). Several markers of bone remodelling (CTx, BALP, P1NP) as well as inflammation (TNFα and IL-1) were elevated. A causative second-site mutation in other genes known to influence bone density was ruled out by sequencing a panel of such genes.
CONCLUSIONS
CONCLUSIONS
If this systemic skeletal cherubism phenotype should be confirmed, it would simplify the treatment of severe cherubism patients and allay reservations about applying a systemic treatment such as those recently published (tacrolimus or imatinib) to a disease heretofore believed to be localised to the jaws.
Identifiants
pubmed: 32825821
doi: 10.1186/s12891-020-03580-z
pii: 10.1186/s12891-020-03580-z
pmc: PMC7441549
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
SH3BP2 protein, human
0
Sh3bp2 protein, mouse
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
564Références
Am J Hum Genet. 1999 Jul;65(1):151-7
pubmed: 10364527
Br J Plast Surg. 2001 Dec;54(8):708-11
pubmed: 11728115
Cell. 2007 Jan 12;128(1):15-7
pubmed: 17218248
J Clin Invest. 2015 Apr;125(4):1396-400
pubmed: 25705883
Clin Chem Lab Med. 2018 May 24;56(6):964-972
pubmed: 29389662
Br J Oral Maxillofac Surg. 2002 Feb;40(1):45-8
pubmed: 11883969
Am J Med. 2009 Jul;122(7):599-604
pubmed: 19559158
J Clin Endocrinol Metab. 2014 Apr;99(4):1196-203
pubmed: 24527713
Cell. 2007 Jan 12;128(1):71-83
pubmed: 17218256
J Bone Miner Res. 2015 May;30(5):878-85
pubmed: 25491283
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 May;81(5):623-8
pubmed: 8734715
Cell. 2011 Dec 9;147(6):1324-39
pubmed: 22153076
J Clin Invest. 2011 Aug;121(8):3244-57
pubmed: 21765218
J Oral Maxillofac Surg. 2019 Jun;77(6):1278.e1-1278.e7
pubmed: 30880133
Int J Oral Maxillofac Surg. 2009 Mar;38(3):218-23
pubmed: 19038533
Hum Pathol. 2016 Dec;58:62-71
pubmed: 27498064
J Bone Miner Res. 2014 Dec;29(12):2618-35
pubmed: 24916406
Orphanet J Rare Dis. 2012 May 24;7 Suppl 1:S5
pubmed: 22640988
Orphanet J Rare Dis. 2018 Sep 20;13(1):166
pubmed: 30236129
Nat Genet. 2001 Jun;28(2):125-6
pubmed: 11381256
J Clin Pathol. 1998 Nov;51(11):831-7
pubmed: 10193324
Clin Chim Acta. 2013 Jan 16;415:169-72
pubmed: 23122966
Bone. 2013 Jan;52(1):347-53
pubmed: 23069372
Ann Plast Surg. 2007 Jun;58(6):645-51
pubmed: 17522488
Mol Syndromol. 2010;1(2):87-90
pubmed: 21045962
J Oral Maxillofac Surg. 1998 Nov;56(11):1336-42
pubmed: 9820222
Bone. 2008 Dec;43(6):1115-21
pubmed: 18793764
JBMR Plus. 2017 Nov 06;2(1):12-21
pubmed: 30283887
Pediatr Pulmonol. 2013 Sep;48(9):927-9
pubmed: 23129383
J Oral Maxillofac Res. 2010 Jul 01;1(2):e2
pubmed: 24421967
Cell Rep. 2014 Sep 25;8(6):1752-1766
pubmed: 25220465
Endocr Dev. 2015;28:176-95
pubmed: 26138842
Orphanet J Rare Dis. 2012 May 24;7 Suppl 1:S6
pubmed: 22640403
Oral Dis. 2001 Mar;7(2):123-30
pubmed: 11355438